Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of IHV01 in Healthy Volunteers
NCT02756208Phase 1Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Nov 2015
- Primary completion
- Jul 2018
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IHV01 in human immunodeficiency virus infection (HIV) (4 arms), sponsored by University of Maryland, Baltimore. Primary endpoints: Local and Systemic Reactogenicity Signs and Symptoms at 48 weeks, Related Adverse Events at 48 weeks and 1 more. Started Nov 2015; status: completed.
02
Drugs
IHV01
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02756208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02756208.